Raffaele Colombo: Insights from October: Advances in ADC research and cancer therapeutics
Raffaele Colombo shared a post on LinkedIn:
“October was extremely busy yet incredibly rewarding:
With Jamie Rich, Paolo Tarantino, Patricia LoRusso, and Elisabeth (Liesbeth) de Vries, we published on AACR Journals Cancer Discovery.
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Authors: Raffaele Colombo, Paolo Tarantino, Jamie R. Rich, Patricia M. LoRusso, Elisabeth G.E. de Vries.
This review started to take shape at the last year AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Targets23) in Boston, thanks to the vision of of Pat and Elisabeth, co-chairs of the ADC session at the meeting, and Elizabeth McKenna. It has been a wonderful year of discussions and collaborations between all the authors.
I was named an honoree of prestigious Pharma Voice 100 list, which recognizes the most inspiring leaders in the life sciences industry. Full list here.
And a little more info clicking on my profile on the Pharma Voice website!
Alongside Giuseppe Curigliano, Paolo Tarantino, and Barbara Pistilli, I presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. Our session focused on fine-tuning the use of ADCs to treat cancer, and my presentation covered ADC target expression / efficacy correlations in the clinic (or lack of).
Andrea Hernández Rojas and Laurence Madera also presented on Zymeworks Inc.
Can’t wait for the exciting times ahead!”
Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023